DeepMed Research

FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

Diet and Systemic Inflammation

Not Applicable

Completed

Conditions: Intestinal Permeability
Type 2 Diabetes Mellitus
Low-grade Chronic Inflammation
Cardiovascular Disease
Obesity

Interventions: Other: High-fructose corn syrup-sweetened beverages
Other: Fructose-sweetened beverages
Other: Glucose-sweetened beverages

First Posted Date: 2011-08-26

Last Posted Date: 2017-08-14

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 25

Registration Number: NCT01424306

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant

Phase 2

Terminated

Conditions: Recurrent Adult Burkitt Lymphoma
Recurrent Grade 3 Follicular Lymphoma
Refractory Chronic Lymphocytic Leukemia
Anaplastic Large Cell Lymphoma
Cutaneous B-cell Non-Hodgkin Lymphoma
Recurrent Grade 1 Follicular Lymphoma
Small Intestine Lymphoma
Splenic Marginal Zone Lymphoma
Adult Nasal Type Extranodal NK/T-cell Lymphoma
Recurrent Adult Diffuse Large Cell Lymphoma

Interventions: Drug: lenalidomide
Biological: rituximab
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2011-08-18

Last Posted Date: 2017-07-27

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 3

Registration Number: NCT01419795

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

MsFLASH-03: Comparative Efficacy of Low-Dose Estradiol and Venlafaxine XR for Treatment of Menopausal Symptoms

Not Applicable

Completed

Conditions: Vasomotor Disturbance
Hot Flashes
Menopause

Interventions: Drug: Venlafaxine XR
Drug: Placebo
Drug: Low-dose 17-ß-estradiol with progesterone taper

First Posted Date: 2011-08-17

Last Posted Date: 2014-08-27

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 339

Registration Number: NCT01418209

Locations: 🇺🇸
Brigham and Women's Hospital, Chestnut Hill, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Harvard Medical School (HU), Boston, Massachusetts, United States
🇺🇸
University of Pennsylvania, UP, Philadelphia, Pennsylvania, United States

and more 1 locations

Scleroderma Treatment With Autologous Transplant (STAT) Study

Phase 2

Completed

Conditions: Systemic Scleroderma

Interventions: Biological: Anti-Thymocyte Globulin
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Cyclophosphamide
Biological: Filgrastim
Other: Laboratory Biomarker Analysis
Drug: Mycophenolate Mofetil
Procedure: Peripheral Blood Stem Cell Transplantation
Drug: Plerixafor
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2011-08-10

Last Posted Date: 2025-01-07

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 21

Registration Number: NCT01413100

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
Boston Medical Center, Boston, Massachusetts, United States
🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

and more 9 locations

Naltrexone for Medication Compliance Among HIV-infected Men With Alcohol Use Disorder

Phase 4

Completed

Conditions: Alcohol Use Disorder
HIV

Interventions: Drug: Placebo pill
Drug: oral naltrexone

First Posted Date: 2011-06-21

Last Posted Date: 2017-06-16

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 159

Registration Number: NCT01377168

Locations: 🇵🇪
Asociación Civil Impacta Salud y Educación, Lima, Peru

COMIDAS Comparing Original Mexican Diets and Standard US Diets

Not Applicable

Completed

Conditions: Healthy

Interventions: Other: Mexican or American foods

First Posted Date: 2011-06-08

Last Posted Date: 2015-05-06

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 50

Registration Number: NCT01369173

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1

Terminated

Conditions: Adult Acute Monoblastic Leukemia (M5a)
Adult Erythroleukemia (M6a)
Adult Pure Erythroid Leukemia (M6b)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Megakaryoblastic Leukemia (M7)
Recurrent Adult Acute Myeloid Leukemia
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)

Interventions: Drug: cyclosporine
Drug: pravastatin sodium
Drug: mitoxantrone hydrochloride
Drug: etoposide
Procedure: bone marrow aspiration

First Posted Date: 2011-04-27

Last Posted Date: 2017-07-02

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 6

Registration Number: NCT01342887

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma

Phase 1

Completed

Conditions: Recurrent Melanoma
Stage IV Melanoma

Interventions: Drug: cyclophosphamide
Biological: aldesleukin
Biological: autologous tumor cell vaccine
Other: laboratory biomarker analysis
Other: immunologic technique
Other: immunohistochemistry staining method
Genetic: polymerase chain reaction
Biological: therapeutic autologous lymphocytes

First Posted Date: 2011-04-21

Last Posted Date: 2014-04-21

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 12

Registration Number: NCT01339663

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Ganciclovir/Valganciclovir for Prevention of CMV Reactivation in Acute Injury of the Lung and Respiratory Failure

Phase 2

Completed

Conditions: Acute Lung Injury
Acute Respiratory Distress Syndrome
Respiratory Failure

Interventions: Drug: IV Ganciclovir
Drug: Placebo

First Posted Date: 2011-04-15

Last Posted Date: 2018-08-21

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 160

Registration Number: NCT01335932

Locations: 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

and more 11 locations

Gene Therapy for Fanconi Anemia

Phase 1

Terminated

Conditions: Fanconi Anemia

Interventions: Procedure: Bone Marrow Aspiration
Biological: Filgrastim
Biological: Genetically Engineered Hematopoietic Stem Progenitor Cells
Other: Laboratory Biomarker Analysis
Procedure: Leukapheresis
Drug: Methylprednisolone
Drug: Plerixafor
Drug: Prednisone

First Posted Date: 2011-04-07

Last Posted Date: 2024-05-17

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 3

Registration Number: NCT01331018

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy